Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
alendronic acid (fosamax) (1 trial)
cyclophosphamide (cytoxan) (1 trial)
doxorubicin (Doxil) (1 trial)
F520 (8 trials)
lenvatinib (lenvima) (2 trials)
Minodronate (1 trial)
prednisone (meticorten) (1 trial)
rituximab (rituxan) (1 trial)
vincristine (oncovin) (1 trial)
carboplatin (paraplatin) (1 trial)
f007 (1 trial)
paclitaxel (taxol) (1 trial)
pemetrexed (alimta) (1 trial)
at-527 (1 trial)
f182112 (1 trial)
orlistat (xenical) (1 trial)
Carcinoma (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Lymphoma (Phase 2)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 2)
Neoplasm Metastasis (Phase 2)
Trials (13 total)
Trial APIs (16 total)